Omeros
Omidria

Leading Cataract Surgeons Discuss Real-World Experience with OMIDRIA

Steve Silverstein - Challenges of miosis including IFIS1-4

Steve Silverstein - Prospective, randomized, double-masked clinical study shows OMIDRIA prevents IFIS4

Keith Walter – My Story with OMIDRIA2,4-7

Keith Walter – Benefits of OMIDRIA to surgeons and patients2,4-7

Keith Walter/Denise Visco – OMIDRIA + topical NSAID alone reduces CME, rebound iritis, and pain/photophobia compared to a post-op regimen of steroid + NSAID2,5-9

Denise Visco – Benefits of OMIDRIA to surgeons and patients2,4,8,9

These videos provide cataract surgeons’ views based on their individual experience and perspective.
Individual experiences may vary.
 

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

  • OMIDRIA must be added to irrigating solution prior to intraocular use.
  • OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
  • Systemic exposure of phenylephrine may cause elevations in blood pressure.
  • Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
  • The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please click here for full Prescribing Information

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Steven Silverstein


Steven Silverstein, MD, FACS

Steven Silverstein, MD, FACS is Clinical Professor of Medicine at Kansas City University of Medicine and Bioscience in Missouri. He is founder and an active practitioner at the Silverstein Eye Centers, also located in Kansas City. Dr. Silverstein has been involved in 80 research studies as a principal investigator. A Fellow of the American College of Surgeons since 1995, he is a member of the American Society of Cataract and Refractive Surgery, the Midwest Cornea Society, and Kansas City Ophthalmology and Otolaryngology.

Dr. Silverstein is a consultant of Omeros Corporation.

Denise M. Visco


Denise M. Visco, MD

Denise M. Visco, MD is Medical Director and founder of Eyes of York. Dr. Visco is a pioneer of cataract surgical advancement being the first female surgeon in the world to perform cataract surgery with the LENSAR Advanced Laser Cataract System. She is also a skilled LASIK surgeon having established her own freestanding laser center in 2000. Additionally, she opened York County's first and only ambulatory surgical center specializing in eye surgery in 2005. Currently she concentrates on customized vision plans for patients desiring refractive cataract and laser surgery.

Dr. Visco is a consultant of Omeros Corporation.

Keith Walter


Keith Walter, MD

Keith Walter, MD is Professor in the Department of Ophthalmology at Wake Forest University School of Medicine. He has been affiliated with Wake Forest for the past 20 years and recently served on the Clinical Advisory Committee for the Institute for Regenerative Medicine. He is also the founder and president of Walter LASIK Technologies. In addition, he is a founding member of the American and European College of Ophthalmic Surgeons. Dr. Walter received his medical degree from Duke University School of Medicine and completed a fellowship in cornea and refractive surgery at Emory University. Dr. Walter holds several patents, including one for a technique using regenerative medicine to grow endothelial cells for corneal transplants.

Dr. Walter is a consultant of Omeros Corporation.

  1. Cho H, et al. Clin Ophthalmol. 2009;3:199–210
  2. Al-Hashimi S, et al. J Cataract Refract Surg. 2018;44:1032–1041
  3. Chang DF, et al. Ophthalmology. 2014;121(4):829–834.
  4. Silverstein SM, et al. J Cataract Refract Surg. 2018;44(9):1103–1108
  5. Rosenberg ED, et al. Clin Ophthalmology. 2018;12:21–28
  6. Kauffman L, Walter K, Hess J. Presentation at the ASCRS-ASOA Annual Meeting; May 7-9, 2019; San Diego, CA
  7. Walter K, Delwadia N, Coben J. J Cataract Refract Surg. 2019;45(4):465–469
  8. Visco D. Clin Ophthalmol. 2018;12:301–305
  9. Visco D, et al. Presentation at the 28th ACES, ABES, and the SEE, Caribbean Eye Meeting; February 1-5, 2019; Cancún, Mexico